Advances in infection-immunity mechanisms and molecular regulatory networks in severe pneumonia-associated lung injury

TL;DR

This paper explores how severe pneumonia causes lung injury through immune system imbalances and proposes new strategies for targeted treatment.

Contribution

The paper introduces a translational framework combining mechanistic research and network modeling for precision intervention in severe pneumonia.

Findings

Persistent inflammation in severe pneumonia leads to progressive lung tissue damage.

Molecular regulatory networks reveal key immune mechanisms driving disease progression.

Current therapeutic strategies face limitations in clinical translation.

Abstract

Severe pneumonia-associated lung injury remains a critical focus in infection and immunology research due to its high lethality and complex immunopathology. Affected patients often present with cellular immune deficiency and an imbalanced interplay between pro-inflammatory and anti-inflammatory mediators, with infection-immunity disequilibrium driving disease progression. The initial infection triggers a defense-injury cascade: while inflammation facilitates pathogen clearance, persistent or excessive activation leads to progressive lung tissue damage. Recent advances have deepened our understanding of immune mechanisms and inflammatory regulation; however, key challenges persist in clinical translation. Here, we synthesize current evidence on the immunopathology of severe pneumonia-associated lung injury, dissect the hierarchical architecture of its molecular regulatory networks, and critically appraise existing therapeutic strategies and their limitations. We propose a translational framework—encompassing mechanistic research, network modelling, and precision intervention—to guide stage-specific regulation and targeted therapy. Finally, we outline the major challenges impeding the clinical application of basic immunological discoveries and highlight future directions for improving patient outcomes.

Figures